Muaiad Kittaneh

A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with <i>NRAS</i>-mutant melanoma: Early encouraging clinical activity.

Jeffrey A. Sosman, Muaiad Kittaneh, Martijn P. Lolkema et al. · Journal of Clinical Oncology · 2014 · 110 citations

Pathology, Tumor Biology, Cpk Elevation +16

Clinical activity of AMG 337, an oral MET kinase inhibitor, in adult patients (pts) with MET-amplified gastroesophageal junction (GEJ), gastric (G), or esophageal (E) cancer.

Eunice L. Kwak, Patricia LoRusso, Omid Hamid et al. · Journal of Clinical Oncology · 2015 · 109 citations

Esophageal Cancer, Cancer Management, Gastroenterology +17

Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors

David S. Hong, Patricia LoRusso, Omid Hamid et al. · Clinical Cancer Research · 2018 · 55 citations · Full text

Detecting germline BAP1 mutations in patients with peritoneal mesothelioma: benefits to patient and family members

Muaiad Kittaneh, Charles Berkelhammer · Journal of Translational Medicine · 2018 · 32 citations · Full text

Clinical and pharmacodynamic (PD) results of a phase I trial with AMP-224 (B7-DC Fc) that binds to the PD-1 receptor.

Jeffrey R. Infante, John D. Powderly, Howard A. Burris et al. · Journal of Clinical Oncology · 2013 · 30 citations

Immunology, Immune Regulation, Immunoediting +20